EVP Jeffrey Baumgartner sold $162K worth of shares at $138.57, reducing his direct holdings by 7.1% while the stock traded just 3.4% above its 90-day low. This follows 13 previous sales and represents routine diversification rather than a high-conviction bearish signal given the STRONG BUY analyst consensus.

Where it could go — Our 1-4 conviction officer sells: 59% beat SPY at 30d; watch $134 as critical support.

EVP Jeffrey Baumgartner exercised options and sold 1,458 shares for $213K at $145.97, just 2.5% above the 90-day low. This appears to be a routine transaction for expiring options rather than a meaningful signal about the insider's outlook.

Where it could go — Our 1-4 conviction officer sells: 57% beat SPY at 30d with +3.0% average outperformance.

EVP Andrew Brannan sold $935K worth of shares at $144.71, a price just 3.2% above the 90-day low, following a same-day option exercise. This is a mechanical transaction with no change to his core holdings, and its significance is muted by the absence of any other insider buyers in the last 60 days.

Where it could go — 8 similar CRUS setups averaged -8.5% at 30d; watch $140.20 as the bear break, $180.42 as the bull trigger.

EVP R&D Jeffrey Baumgartner sold $197K in CRUS shares at $168.23, reducing his direct holdings by 6.7% while the stock traded 6.8% below its 90-day high. This continues his established pattern of consistent selling with no buying history, though the modest size and lack of cluster support make it less concerning than larger disposals.

Where it could go — 7 similar CRUS signals averaged -3.1% at 30d; watch $156 as bear break level, $180 as resistance.

Baumgartner Jeffrey W exercised 3,907 options at $41.49 and sold the resulting shares at $168.54 ($658K). The sale came from newly exercised options and did not reduce previously held shares, leaving 17,575 directly held shares.

Where it could go — Exercise-and-sell transactions are largely mechanical and carry limited directional signal.

THOMAS SCOTT exercised 1,300 options at $78.00 and sold the resulting shares at $180.04 ($234K). The sale came from newly exercised options and did not reduce previously held shares, leaving 31,048 directly held shares.

Where it could go — Exercise-and-sell transactions are largely mechanical and carry limited directional signal.

Jeffrey W. Baumgartner sold 11,171 shares at ~$171.65 ($1.9M); 10,000 of them came from a same-day option exercise at $38.34. The remaining 1,171 shares came from existing holdings, leaving 17,575 directly held shares.

Where it could go — Minimal reduction of existing holdings—about 10% of the sale trimmed direct shares, with the bulk sourced from option exercise proceeds.

EVP Brannan sold $289K worth of CRUS shares at $175.75, reducing his stake by 18.6% near the stock's 90-day high. This first-time sale follows similar recent insider selling activity at CRUS, creating a concerning pattern despite the stock's strong analyst buy rating.

Where it could go — Analyst mean target unavailable; bear case if stock breaks below $156 support level.

Justin E. Dougherty, EVP Global Operations, sold 2,000 shares at approximately $166.50 ($333K); 1,080 shares came from a same-day option exercise at no cost. The remaining 920 shares came from existing holdings, leaving 4,537 shares directly held.

Where it could go — Modest trim of existing holdings—over half the sale was from options exercised at no cost, with the remainder reducing direct stock position.

Director Alexander Davern sold $159K in shares, reducing his stake by 4.6% at a price 11.2% below the 90-day high. This first-time sale is a negative initiation but lacks a confirming cluster and was not executed at a price extreme, making it a weak standalone signal.

Where it could go — Analyst mean target not provided; bear case if stock breaks the recent 30-day low of $156.25.

CEO John Forsyth executed a Code-S open-market sale of 5,000 shares at $170.41 on 2026-05-08, reducing his stake by 6.7% (75,016 to 70,016 shares) and realizing $852K. This is Forsyth's first-ever Form 4 Code-S filing on record; he has no prior open-market purchases or sales, and no other officers bought CRUS in the past 60 days. The transaction occurred at mid-range pricing (33% above the 90-day low of $127.75, 5% below the 90-day high of $179.00), with 14-analyst consensus at BUY (10 buy, 4 hold, 0 sell).

Where it could go — If this represents portfolio rebalancing rather than conviction shift, the BUY consensus and mid-range entry price suggest historical support near $148–$170; invalidated if stock breaks below the 90-day low of $127.75 or if additional officer sales cluster within 30 days.